[1] GROSSMAN N T, CASADEVALL A.Physiological Differences in Cryptococcus neoformans strains in vitro versus in vivo and their effects on antifungal susceptibility[J].Antimicrob Agents Chemother, 2017, 61(3):e02108-16. [2] CLSI.Epidemiological cutoff values for antifungal susceptibility testing[S].3rd ed.CLSI supplement M59, 2020. [3] RAJASINGHAM R, SMITH R M, PARK B J, et al.Global burden of disease of HIV-associated cryptococcal meningitis:an updated analysis[J].Lancet Infect Dis, 2017, 17(8):873-881. [4] MCKENNEY J, BAUMAN S, NEARY B, et al.Prevalence, correlates, and outcomes of cryptococcal antigen positivity among patients with AIDS, United States, 1986-2012[J].Clin Infect Dis, 2015, 60(6):959-965. [5] FANG W, FA Z, LIAO W.Epidemiology of Cryptococcus and cryptococcosis in China[J].Fungal Genet Biol, 2015, 78:7-15.DOI:10.1016/j.fgb.2014.10.017. [6] PERFECT J R, BICANIC T.Cryptococcosis diagnosis and treatment:What do we know now[J].Fungal Genet Biol, 2015, 78:49-54.DOI:10.1016/j.fgb.2014.10.003. [7] 曹彬, 蔡柏蔷, 王辉, 等.肺部真菌感染152例病原谱再评价[J].中华结核和呼吸杂志, 2007, 30(4):279-283. [8] DONNELLY J P, CHEN S C, KAUFFMAN C A, et al.Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group education and Research Consortium[J].Clin Infect Dis, 2020, 71(6):1367-1376. [9] 范欣, 肖盟, 王贺, 等.新型隐球菌显色微量肉汤稀释法药敏流行病学折点的建立[J].中华医院感染学杂志, 2016, 26(10):2215-2218. [10] 樊红丽, 高丽, 毛小琴, 等.云南省艾滋病患者分离新生隐球菌的药物敏感性检测与分析[J].中国感染控制杂志, 2019, 18(4):340-343. [11] PERFECT J R, DISMUKES W E, DROMER F, et al.Clinical practice guidelines for the management of cryptococcal disease:2010 update by the infectious diseases society of America[J].Clin Infect Dis, 2010, 50(3):291-322. [12] 温海.隐球菌感染诊治专家共识[J].中国真菌学杂志, 2010, 5(2):65-68, 86. |